Stocks have kept up the market's record rise today after the Dow Jones Industrial Average (DJINDICES: ^DJI ) hit a new all-time high to close last week's run. Boeing (NYSE: BA ) has come back in a big way from Friday's Dreamliner-fire-fueled plunge, although the rest of the Dow has risen only slightly, and blue-chip stocks are split evenly between risers and losers. Let's catch up on the stories you need to know.
Boeing lifts off
Boeing's shares have bounced back with a 3.7% gain today, leading the Dow after an early probe of the 787 Dreamliner fire at London's Heathrow airport last week didn't �indict the plane's battery as a cause of the incident. That's a relief for Boeing investors after the 787's battery-caused grounding dominated talk of the company for the majority of early 2013. Still, the company's PR headaches regarding its newest airliner haven't stopped its stock from shooting up by more than 32% year to date.
Given the company's impressive backlog of commercial aircraft and renewed orders for the 787, it's hard to imagine that the Heathrow fire will do much, if anything, to slow this stock down, outside the dent it inflicted on Friday. Even as sequestration's budget cuts impact Boeing's defense division, this company's commercial airline segment has stepped up to outpace any losses.
Top Companies To Buy Right Now: Pain Therapeutics Inc (PTIE)
Pain Therapeutics, Inc., incorporated in May 1998, is a biopharmaceutical company that develops drugs. The Company has four drug candidates in clinical programs, including REMOXY, abuse-resistant hydromorphone, abuse-resistant hydrocodone and a radio-labeled monoclonal antibody to treat metastatic melanoma. It is also working on a new treatment for patients with hemophilia. The Company�� lead drug candidate is REMOXY, which is a painkiller. It has collaboration agreement with King Pharmaceuticals, Inc. (King) develops and commercializes REMOXY and other opioid painkillers. The Company and King jointly managed a Phase III clinical program and New Drug Application (NDA) submission for REMOXY. It is also developing a pipeline of drug candidates in the area of oncology and hematology. It owns all commercial rights to its pipeline of drug candidates in oncology and hematology. As of December 31, 2010, the Company leased approximately 30,700 square feet of space in San Mateo, California and all of its operations are located in San Mateo.
REMOXY
REMOXY is a controlled-release oral capsule form of oxycodone in a highly viscous liquid formulation matrix that includes excipients. It is formulated to help address issues of abuse and misuse of time-release oxycodone tablets. REMOXY�� capsule dosage form provides therapeutic drug levels of oxycodone on a twice-daily dosing schedule, while resisting the rapid increases in plasma levels of oxycodone associated with common methods of abuse and misuse. Its formulation also resists delivery by unapproved routes of administration, such as injection, snorting or inhalation.
Metastatic Melanoma
The Company is developing a drug candidate called PTI-188 to treat metastatic melanoma, a form of skin cancer. PTI-188 is a monoclonal antibody linked to a radioisotope, intended to deliver doses of radiation lethal to melanoma tumors without harming normal tissue. In March 2010, the Company announced data from two open-label! , dose-escalating Phase I studies conducted in Israel to assess the safety, pharmacokinetics, dosimetry and anti-tumor activity of PTI-188. During the year ended December 31, 2010, the second study was completed. The technology used in this program was developed at the Albert Einstein College of Medicine (AECOM). It had licensed worldwide commercial rights to this technology from AECOM.
Hemophilia
The Company has a gene transfer program, initially developed at Stanford University, focused at correcting a genetic disorder in which patients are unable to stop bleeding. During 2010, it conducted a variety of pre-clinical studies with this technology. The Company has licensed worldwide commercial rights to the technology used in this program from Poetic Genetics, LLC (Poetic).
Other product candidates
The Company�� alliance with King includes development of three other abuse-resistant opioid product candidates: hydromorphone, hydrocodone and oxymorphone. Its abuse-resistant formulations of hydromorphone and hydrocodone have completed Phase I clinical trials. In January 2011, the Company announced that the Food and Drug Administration (FDA) had accepted its investigational IND, for abuse-resistant oxymorphone.
The Company competes with Roxane Laboratories, Purdue Pharma, King Pharmaceuticals, Inc., Abbott Laboratories, Cephalon, Endo Pharmaceuticals, Teva Pharmaceuticals, Elkins-Sinn, Watson Laboratories, Ortho-McNeil Pharmaceutical and Forest Pharmaceuticals.
Advisors' Opinion:- [By Jessica Alling]
Elsewhere, Pfizer is evaluating its continued partnership on an experimental oxycodone capsule, Remoxy. The drug is an extended-release formula that is targeted at reducing abuse of the painkiller. After years of setbacks and postponements for FDA approval, Pfizer is weighing its options. Its partners for the drug, Pain Therapeutics (NASDAQ: PTIE ) and Durect, have both fallen heavily due to the news, with Pain Therapeutics falling more than 50% -- its largest decline ever.
- [By Sean Williams]
However, all isn't well when it comes to the future of abuse-resistant painkiller Remoxy, which was developed by Pain Therapeutics (NASDAQ: PTIE ) , using Durect's�special technology-based gel capsule to prevent abuse, and is licensed by Pfizer (NYSE: PFE ) . Remoxy has been rejected twice by the FDA -- the most recent coming in mid-2011 -- and Pfizer commented this morning that if it were to seek reapproval for the drug it wouldn't be for at least two more years. Given Pfizer's extensive product pipeline, losing Remoxy wouldn't be a big deal. For micro-cap clinical-stage companies like Pain Therapeutics and Durect, it'd be a gigantic blow. Fittingly, Pain Therapeutics and Durect shares imploded by 50% and 34%, respectively, on Friday.
Top Healthcare Technology Stocks To Buy Right Now: Franklin Electric Co. Inc.(FELE)
Franklin Electric Co., Inc., together with its subsidiaries, engages in the design, manufacture, and distribution of groundwater and fuel pumping systems. It operates in two segments, Water Systems and Fueling Systems. The Water Systems segment provides motors, pumps, electronic controls, and related parts and equipment primarily for use in groundwater, wastewater, and fuel transfer applications. Its motors and pumps are used principally for pumping fresh water and wastewater in various residential, agricultural, and industrial applications. This segment also offers electronic drives and controls for the motors, which control functionality and provide protection from various hazards, such as electric surges, over-heating, or dry wells and tanks. The Fueling Systems segment provides pumps, pipe, sumps, fittings, vapor recovery components, electronic controls, monitoring devices, and related parts and equipment primarily for use in submersible fueling system applications. It also integrates and sells motors and electronic controls produced by the Water Systems segment. The company sells its products and related equipment to specialty distributors, original equipment manufacturers, industrial and petroleum equipment distributors, and oil and utility companies through its sales force and independent manufacturing representatives primarily in the United States, Europe, South Africa, Brazil, Mexico, and China. Franklin Electric Co., Inc. was founded in 1944 and is headquartered in Bluffton, Indiana.
Advisors' Opinion:- [By Seth Jayson]
When judging a company's prospects, how quickly it turns cash outflows into cash inflows can be just as important as how much profit it's booking in the accounting fantasy world we call "earnings." This is one of the first metrics I check when I'm hunting for the market's best stocks. Today, we'll see how it applies to Franklin Electric (Nasdaq: FELE ) .
- [By Seth Jayson]
Margins matter. The more Franklin Electric (Nasdaq: FELE ) keeps of each buck it earns in revenue, the more money it has to invest in growth, fund new strategic plans, or (gasp!) distribute to shareholders. Healthy margins often separate pretenders from the best stocks in the market. That's why we check up on margins at least once a quarter in this series. I'm looking for the absolute numbers, so I can compare them to current and potential competitors, and any trend that may tell me how strong Franklin Electric's competitive position could be.
Top Healthcare Technology Stocks To Buy Right Now: Catalyst Pharmaceutical Partners Inc.(CPRX)
Catalyst Pharmaceutical Partners, Inc., a development-stage biopharmaceutical company, focuses on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of drug addiction and epilepsy. It is evaluating its lead product candidate, CPP-109, a GABA aminotransferase inhibitor candidate, which is under Phase II(b) clinical trial for the treatment of cocaine addiction, as well as focuses on evaluating CPP-109 for the treatment of other addictions and obsessive-compulsive disorders. The company is also developing CPP-115, a GABA aminotransferase inhibitor for various indications, including drug addiction, epilepsy, and for other selected central nervous disease indications. It has license agreements with Brookhaven Science Associates, LLC on various patents and patent applications relating to the use of vigabatrin as a treatment for cocaine and other addictions, and obsessive-compulsive disorders; and with Northwestern University to commercialize GABA aminotransferase inhibitors worldwide, as well as a definitive clinical trial agreement with the National Institute on Drug Abuse to jointly conduct a U.S. Phase II(b) clinical trial evaluating CPP-109 for the treatment of cocaine addiction. Catalyst Pharmaceutical Partners, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Advisors' Opinion:- [By John Udovich]
While the Twitter IPO has been grabing everyone�� attention, biotech IPOs continue to dominate both biotech and IPO news with Karyopharm Therapeutics Inc (NASDAQ: KPTI) going public yesterday and�Relypsa (NASDAQ: RLYP), TetraLogic Pharmaceuticals (NASDAQ: TLOG), Vital Therapies (NASDAQ: VTL) and Xencor (NASDAQ: XNCR) filing to go public in the near future�(despite the sector producing some�ugly charts�for the month of October) plus�another small cap called TNI BioTech (OTCMKTS: TNIB) has also been producing a steady flow of news:
Karyopharm Therapeutics Debuts. Yesterday, small cap Karyopharm Therapeutics, which is working on a drug that aids the body�� natural tumor-suppressing proteins,�debuted at the top of�its range to raise $109 million in an upsized�offering of 6.8 million shares at $16 apiece with shares closing at $16.81. It should be noted that Karyopharm Therapeutics��lead drug candidate (Selinexor) is in early-stage clinical trials�and the company lost�lost nearly $12.5 million on revenue of $366,000 during the first six months of this year. Biotech IPOs by Region. On an interesting note, Luke Timmerman, the National Biotech Editor of Xconomy, has written a�good�article tracking biotech or life sciences IPOs by region. By his count, Boston is home to eight of the 45 (18%) of the life sciences IPOs this year (its companies have also�raised the most money - about $770 million)�plus�the New York/northern New Jersey region is also home to�eight. San Diego�came in third with six IPOs followed by San Francisco with five while only five of the 45 biotech IPOs�came from outside the�US (Three from Israel and two from Europe). However, the above figures may change as by his account, there are 15 additional biotech companies in line to go public. More Biotechs Set IPO Terms. The small cap biotech space is about to be joined by a few new additions as a couple of biotechs file to go public�over the past�week or so: Relypsa, which is d - [By Roberto Pedone]
One under-$10 biopharmaceutical player that's starting to move within range of triggering a big breakout trade is Catalyst Pharmaceutical Partners (CPRX), which is focused on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of drug addiction and epilepsy. This stock has been on fire so far in 2013, with shares up a whopping 364%.
If you take a look at the chart for Catalyst Pharmaceutical Partners, you'll notice that this stock has been uptrending strong for the last month, with shares soaring higher from its low of $1.29 to its intraday high of $2.09 a share. During that uptrend, shares of CPRX have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed share of CPRX within range of triggering a big breakout trade.
Traders should now look for long-biased trades in CPRX if it manages to break out above its 50-day moving average of $2.11 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average volume of 2.21 million shares. If that breakout triggers soon, then CPRX will set up to re-test or possibly take out its next major overhead resistance levels at $2.87 to $3 a share. Any high-volume move above those levels will then give CPRX a chance to re-test its 52-week high at $3.65 a share.
Traders can look to buy CPRX off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $1.65 to $1.63 a share. One can also buy CPRX off strength once it starts to take out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
Top Healthcare Technology Stocks To Buy Right Now: Endeavour International Corp (END)
Endeavour International Corporation (Endeavour), incorporated on January 13, 2000, is an independent oil and gas company engaged in the exploration, development and acquisition of energy reserves in the United States and United Kingdom. The Company has three producing fields in the United Kingdom, including Alba, Bacchus and Bittern, as well as a number of development projects including Rochelle and Columbus. In the United States, the Company has production in the Haynesville and Marcellus, as well as two oil frontier plays in Colorado and Montana. As of December 31, 2012, Endeavour had proved reserves of 71,591 million cubic feet (MMcf) of natural gas and 13,739 thousands of barrels (Mbbls) of crude oil for a combined 25.7 million barrels of oil equivalent (MBOE).
The North Sea is a resource area where it has a development project, producing properties and additional exploration licenses. During 2012, Alba production volumes were impacted by water handling issues. As of December 31, 2012, it held a 30% working interest in its Bacchus field asset, which is operated by Apache Corporation, who owns a 50% working interest. In April and July 2012, it achieved production from the first and second development wells, respectively, on the Bacchus field. The Company�� working interest in the Rochelle area is 44% and it is the operator of the field, which is comprised of Blocks 15/26b, 15/26c and 15/27. Its United States activity has targeted reserve and production growth in shale gas plays, including the Louisiana Haynesville and Pennsylvania Marcellus areas.
The Company is also targeting emerging oil-prone and liquids-rich plays, including the Montana Heath oil play and its new interests in the Colorado Niobrara area. The Company operates and controls the Marcellus assets while retaining a 50% position in its remaining producing Haynesville acreage. The Company has 19 Haynesville Units which held by production with an estimated over 80 remaining gross locations to be developed, dep! ending on development well spacing. The Company has interests in approximately 88,900 net acres in the emerging Heath Shale oil play in Montana, primarily in Rosebud and Garfield Counties.
Advisors' Opinion:- [By Jake L'Ecuyer]
Energy shares dropped by 0.26 percent in the US market today. Among the sector stocks, Endeavour International (NYSE: END) was down more than 5.6 percent, while Pacific Ethanol (NASDAQ: PEIX) tumbled around 2.2 percent.
- [By Paul Ausick]
Stocks on the Move: Alcoa Inc. (NYSE: AA) is up 9.1% at $9.38 after posting a new 52-week high of $9.63 earlier today. Endeavour International Corp. (NYSE: END) is down 14.3% at $6.05 after failing to get any appreciable results from its strategic review. E-commerce China Dangdang Inc. (NYSE: DANG) is down 13.4% at $10.05 after issuing a warning on third-quarter earnings.
- [By Paul Ausick]
Last February independent oil & gas company Endeavour International Corp. (NYSE: END) initiated a strategic review to help it ��urther enhance shareholder value.��The company needed the help. Its size works against it. At the time of its announcement, the company�� market cap was just around $225 million.
No comments:
Post a Comment